Patents by Inventor Markus Heidenblad

Markus Heidenblad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Micromirs
    Patent number: 10450564
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 22, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • MICROMIRS
    Publication number: 20180201928
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 19, 2018
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • MICROMIRs
    Patent number: 9790493
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: October 17, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • MICROMIRs
    Publication number: 20150299699
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: October 29, 2014
    Publication date: October 22, 2015
    Inventors: Susanna OBAD, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • MicromiRs
    Patent number: 8906871
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: December 9, 2014
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • MicroRNAs
    Patent number: 8288356
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 16, 2012
    Assignee: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad
  • MICROMIRs
    Publication number: 20100298410
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: October 3, 2008
    Publication date: November 25, 2010
    Inventors: Susana Obad, Sakari Kauppinen, Joacim Elmén, Morten Lindow, Markus Heidenblad
  • MICROMIRs
    Publication number: 20090143326
    Abstract: The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
    Type: Application
    Filed: October 3, 2008
    Publication date: June 4, 2009
    Applicant: Santaris Pharma A/S
    Inventors: Susanna Obad, Sakari Kauppinen, Joacim Elmen, Morten Lindow, Markus Heidenblad